Health

Trump's Surgeon General Pick Called “Big Pharma’s Worst Nightmare”

The pharmaceutical industry may be facing a formidable new challenger at the highest level of U.S. public health leadership. On Wednesday, President Donald Trump announced the nomination of Dr. Casey Means as U.S. Surgeon General—an outspoken critic of what she calls a “profit-driven” healthcare system and a prominent voice within the “Make America Healthy Again” (MAHA) movement. Means’s views on chronic illness, pharmaceutical overreach, and systemic reform have made her a champion to some and a lightning rod to others. Her nomination, which follows the abrupt withdrawal of former nominee Dr. Janette Nesheiwat, signals a sharp pivot in federal health priorities—and is already being described by some observers as “Big Pharma’s biggest nightmare.” A Stanford Medical School graduate and former surgical resident, Means left clinical practice before completing her training at Oregon Health & Science University, citing disillusionment with conventional medicine. She has since redefined he...